Glaukos (NYSE:GKOS) today announced positive outcomes from two Phase 3 pivotal trials for its iDose TR system. iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to reduce intraocular pressure (IOP). Glaukos designed it to continuously release therapeutic levels of medication for at least one year. Once all travoprost is released, iDose […]
Optical/Ophthalmic
Second Sight Medical merges with Nano Precision Medical, rebrands as Vivani Medical
Second Sight Medical (Nasdaq:EYES) announced today that it completed its merger with Nano Precision Medical and rebranded. In February, the two companies entered into a definitive agreement under which Nano Precision Medical (NPM) would merge with a wholly-owned subsidiary of Second Sight in an all-stock transaction, with NPM the surviving company under Second Sight’s ownership. […]
Bausch Health takes step toward separating Bausch+Lomb
Bausch Health (NYSE:BHC) announced today that it transferred shares of its Bausch + Lomb to an existing subsidiary. The Laval, Quebec–based company transferred common shares in an amount equal to approximately 38.6% of the issued and outstanding shares of Bausch + Lomb to an existing, wholly-owned, unrestricted subsidiary of the company. According to a news […]
Lensar announces first patients treated with Ally adaptive cataract treatment
Lensar today announced the first commercial cases were performed with its Ally adaptive cataract treatment system. The first procedures were performed by Dr. Robert Weinstock at The Eye Institute of West Florida, where he performed 15 laser-assisted cataract surgery cases following the recent installation of the Ally system. Ally was FDA cleared in June 2022 […]
Data supports Sight Sciences’ Omni surgical system for glaucoma
Sight Sciences (Nasdaq:SGHT) announced today that 36-month data supports the use of its Omni surgical system. Data from the three-year post-surgery follow-up demonstrates that the Omni surgical system delivers safe, consistent and durable results in adult patients with open-angle glaucoma (OAG) on a standalone basement. Menlo Park, California–based Sight Sciences evaluated the Omni system in […]
Alcon lowers its 2022 forecast amid strong dollar
Alcon (SIX/NYSE:ALC) posted Street-beating second quarter results but lowered its 2022 guidance amid a challenging macroeconomic environment. The Geneva-based eye care tech giant announced yesterday evening that it earned $148 million, or 30¢ per share, off $2.22 billion in sales during the quarter ended June 30, 2022, for a bottom-line decline of 2% and a […]
Glaukos stock dips on big Q2 earnings miss
Glaukos (NYSE:GKOS) shares were down this morning on second-quarter results that missed the consensus earnings forecast. The Aliso Viejo, California–based glaucoma treatment developer posted losses of $45.5 million, or 96¢ per share, on sales of $72.7 million for the three months ended June 30, 2022, for a bottom-line slide deeper into the red on a […]
FDA approves AcuFocus intraocular lens for cataract surgery
AcuFocus announced today that it received FDA approval for its IC-8 Apthera intraocular lens for the treatment of cataracts. Irvine, California-based AcuFocus said in a news release that the Apthera IOL represents the first and only non-toric, extended depth of focus IOL approved for the 82% of cataract patients who have as much as 1.5 […]
Bausch + Lomb CEO to step down
Bausch + Lomb (NYSE:BLCO) announced today that Joseph C. Papa will step down as the company’s board chair and CEO. The optical and ophthalmic device maker has appointed Thomas W. Ross, Sr., to serve as its chair and has begun the search for a new CEO. Papa will remain as CEO and a member of […]
FDA clears Lensar Ally cataract treatment system
Lensar (Nasdaq:LNSR) announced today that it received FDA 510(k) clearance for its next-generation Ally system. Orlando, Florida–based Lensar designed the Ally adaptive cataract treatment system to enable cataract surgeons to complete the femtosecond-laser-assisted cataract (FLACS) procedure seamlessly in a single, sterile environment. According to a news release, the company intends to deliver the first Ally […]
Ocular Therapeutix adds two executives to leadership team
Ocular Therapeutix (Nasdaq:OCUL) announced today that it made two additions to its executive leadership team. Bedford, Massachusetts-based Ocular Therapeutix appointed a chief medical advisor (CMA) — a newly created role — as well as a new chief medical officer (CMO). Additionally, the company created a new role called chief strategy advisor (CSA) for its departing […]